Summary of Key Information:
Reporting Period (Quarter/Year): Not Specified
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI LODR
Audit Opinion:
Not Specified
Key Financial Highlights:
Not Specified
Standalone Results:
Not Specified
Consolidated Results:
Not Specified
Segment-wise Performance:
Not Specified
Corporate Actions:
- ESOP Allotment: The Board approved allotment of 1,475 equity shares of ₹10 each to an eligible employee upon exercise of options vested under Entero Employee Stock Option Plan 2023
- Exercise price: ₹804 per equity share
- Premium: ₹794 per equity share
- Distinctive share numbers: 4,35,21,598 to 4,35,23,072
- Total issued share capital after issue: ₹43,52,30,720
- Total issued shares after this issue: 4,35,23,072
- Shares rank pari-passu with existing equity shares
- No lock-in period restrictions except as required under applicable laws
- Director Reappointment: Board approved revised tenure for reappointment of Mr. Rajesh Shashikant Dalal (DIN: 03504969) and Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Directors, subject to shareholder approval at ensuing AGM
- Tenure of Mr. Sujesh Vasudevan (DIN: 08240092) remains unchanged
- Revision facilitates effective succession planning and smoother transition in board composition
Other Significant Information:
- Reference to earlier intimation dated May 25, 2026, Ref. No.: 06/SE/LC/2026-27
- Information available on company website: www.enterohealthcare.com